- Home
- GNFT
GNFT
GENFIT S.A.
as 07-26-2024 4:00pm EST
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 225.4M | IPO Year: | 2019 |
| Target Price: | $13.00 | AVG Volume (30 days): | 6.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.89 - $6.05 | Next Earning Date: | 04-04-2024 |
| Revenue: | $42,417,778 | Revenue Growth: | 43.70% |
| Revenue Growth (this year): | 150.53% | Revenue Growth (next year): | -53.26% |
Latest GENFIT S.A. News
GNFT Breaking Stock News: Dive into GNFT Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 hours ago
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis
GlobeNewswire
17 days ago
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
GlobeNewswire
a month ago
GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH
MT Newswires
2 months ago
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment
GlobeNewswire
2 months ago
GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis
GlobeNewswire
2 months ago
GENFIT to Present Latest ACLF Research at EASL Congress™ 2024
GlobeNewswire
2 months ago
GENFIT: May 22, 2024 Combined Shareholders Meeting Results
GlobeNewswire
2 months ago
GENFIT Reports First Quarter 2024 Financial Information
Compare GNFT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNFT GENFIT S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.